Antibiotic-resistant gonococci - Past, present and future

South African Medical Journal

Volumn 97, Issue 11 III, 2007, Pages 1146-1150

  Lewis, David A ^a,b,c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFIXIME; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORTETRACYCLINE; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; NALIDIXIC ACID; OPIATE; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; PERMANGANATE POTASSIUM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; SULFAMIDOCHRYSOIDINE; SULFANILAMIDE; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; CHROMOSOME; CONDOM; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDIDYMITIS; GASTROINTESTINAL SYMPTOM; GONORRHEA; HUMAN; IN VIVO STUDY; NONHUMAN; ORCHITIS; PELVIC INFLAMMATORY DISEASE; PLASMID; RECOMMENDED DRUG DOSE; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SOUTH AFRICA; STRAIN DIFFERENCE; URETHRITIS; URINE RETENTION;

CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; MACROLIDES; MALE; NEISSERIA GONORRHOEAE; PENICILLINS; QUINOLONES; SPECTINOMYCIN; TETRACYCLINES;

EID: 37349084185     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cohen MS, Sparling PF. Mucosal infection with Neisseria gonorrhoeae. Bacterial adaptation and mucosal defences. J Clin Invest 1992; 89: 1699-1705.
2. Clarkson ERT. Gonorrhoea in the male. In: Clarkson ERT, ed. The Venereal Clinic. London: John Bale, Sons & Danielsson Ltd, 1922: 75-252.
3. Kampmeier RH. Introduction of sulphonamide therapy for gonorrhoea. Sex Transm Dis 1983; 10: 81.
4. Reyn A, Korner B, Benzton MW. Effects of penicillin, streptomycin and tetracycline on Neisseria gonorrhoeae isolates in 1944 and 1957. Br J Venereal Dis 1958; 34: 227-239.
5. Percival A, Rowlands J, Corkhill JE et al. Penicillinase-producing gonococci in Liverpool. Lancet 1976; 2: 1379-1382.
6. Centers for Disease Control. Penicillinase-producing Neisseria gonorrhoeae. MMWR Morb Mortal Wkly Rep 1976; 25: 261.
7. Reyn A. Sensitivity of N. gonorrhoeae to antibiotics. Br J Venereal Dis 1961; 37: 145-157.
8. Morse SA, Johnson SR, Biddle JW, Roberts MC. High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant. Antimicrob Agents Chemother 1986; 30: 664-670.
9. Roberts MC, Wagenvoort JHT, Van Klingeren B, Knapp JS. tetM- and β-lactamase-containing Neisseria gonorrhoeae (tetracycline resistant and penicillinase producing) in the Netherlands. Antimicrob Agents Chemother 1988; 32: 158.
10. Boslego JW, Tramont EC, Takafuji ET et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987: 317; 272-278.
11. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Nisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997; 8: 299-302.
12. Roberts MC, Chung WO, Roe D, et al. Erythromycin-resistant Neisseria gonorrhoeae and oral commensal Neisseria spp. carry known rRNA methylase genes. Antimicrob Agents Chemother 1999; 43: 1367-1372.
13. Rouquette-Loughlin CE, Balthazar JT, Shafer WM. Characterisation of the MacA-MacB efflux system in Neisseria gonorrhoeae. J Antimicrob Chemother 2005; 56: 856-860.
14. Ison CA, Woodford PJ, Madders H, Claydon E. Drift in susceptibility of Neisseria gonorrhoeae to ciprofloxacin and emergence of therapeutic failure. Antimicrob Agents Chemother 1998; 42: 2919-2922.
15. Gransden WR, Warren CA, Phillips I, Hodges M, Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet 1990; 335: 51.
16. Giles JA, Falconio J, Yuenger JD, Zenilman JM, Dan M, Bash MC. Quinolone resistance-detemining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. J Infect Dis 2004: 189: 2085-2093.
17. Martin IM, Hoffman S, Ison CA, ESSTI Network. European surveillance of sexually transmitted infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J Antimicrob Chemother 2006; 58: 587-593.
18. Moodley P, Moodley D, Sturm AW. Ciprofloxacin resistant Neisseria gonorrhoeae in South Africa. Int J Antimicrob Agents 2004; 24: 192-193.
19. Koornhof HJ, Moodley P, Slabbert M, et al. A national survey of antimicrobial resistance in gonococci isolated in South Africa. Oral Presentational the 1st Joint Congress of the Federation of Infectious Diseases Societies of South Africa, Sun City, 24-27 July 2005.
20. Wang SA, Lee MV, O'Connor N, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime - Hawaii, 2001. Clin Infect Dis 2003; 37: 849-852.
21. Ito M, Deguchi T, Mizutani KS, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harbouring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005; 49: 137-143.
22. Ameyama S, Onodera S, Takahata M, et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002; 46: 3744-3749.
23. Takahata S, Senju N, Osaki Y, Yoshida T, Ida T. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006; 50: 3638-3645.
24. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997; 349: 1868-1873.
25. Furuya R, Nakayama H, Kanayama A, et al. In vitro synergistic effects of double combinations of beta lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006; 12: 172-176.